Tag: EPO

Patenting Antibody and Cell Therapies – What to Do and What Not to Do

Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great

Read more...

Clarifying the patentability of medical use inventions in China

At the end of 2019, the new Coronavirus (2019-nCoV) emerged. It has gone on to infect millions of people

Read more...

EPO rules plants and animals exclusively obtained by essentially biological processes not patentable

It has been clear that essentially biological processes for the production of plants or animals are explicitly excluded from

Read more...

The Crispr-Cas9 patent tussle continues: The case of UC Berkeley at the EPO

In Europe, we don’t do things the way the Americans do… Oral proceedings in the opposition against UC Berkeley’s

Read more...

Denmark champions patents as fundamental to preventing climate change

Danish Minister for Industry, Business and Financial Affairs Simon Kollerup stated that protecting the intellectual property rights of innovative

Read more...

EPO and EUIPO study finds link between IPR and SME growth

A recent study by EPO and EUIPO explores the relationship between prior IPR activities of SMEs and the likelihood

Read more...
Antibodies

Antibodies vs. the EPO – What scope of protection?

Antibodies are currently enjoying great attention and are, together with their derivations and combined applications, growing to occupy centre

Read more...

CRISPR patent revoked at the EPO

The CRISPR system has revolutionised the gene technology field, opening up for a multitude of genetic engineering possibilities and

Read more...

IP within IoT and the fourth industrial revolution

According to a new study Patents and the Fourth Industrial Revolution (4IR), conducted by the EPO the number of

Read more...
EPO and Brazilian Patent Office launches new PPH agreement

EPO and Brazilian Patent Office launch new PPH agreement

The ever expanding PPH (Patent Prosecution Highway) network has once again gotten a new addition, and as always AWA

Read more...

Mobile Sliding Menu